fbpx

Day

december 8, 2015
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...

Nyheder

Danmark får sin første kandidatuddannelse i neurovidenskab
4. juni 2020
Nye alkohol-gener vælter frem
2. juni 2020
Video: Mød fem professorer, der har viet deres hjerne til andres
14. maj 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge